Ranibizumab Treatment for Retinal Vein Occlusion
Not Applicable
- Conditions
- Macular Edema Due to BRVO/CRVO
- Interventions
- Drug: Ranibizumab, 0.5mg, Intravitreal
- Registration Number
- NCT01968616
- Lead Sponsor
- Kyoto University, Graduate School of Medicine
- Brief Summary
In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Signed informed consent form
- Male or female of aged 18 years or older
- Macula edema secondary to BRVO/CRVO
- Decrease of VA due to macular edema
Exclusion Criteria
- Prior episode of RVO
- Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye)
- Ocular disorders in the study eye that may confound interpretation of study results
- History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO
- The pregnant or lactating woman
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Intravitreal Lucentis 0.5mg Ranibizumab, 0.5mg, Intravitreal One arm
- Primary Outcome Measures
Name Time Method Mean foveal thickness measured by SD-OCT 2 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Ophthalmology, Kyoto University Hospital
🇯🇵Kyoto, Japan